← Back to All US Stocks

RMHI Stock Analysis 2026 - Retrieve Medical Holdings, Inc. AI Rating

RMHI OTC Pharmaceutical Preparations NV CIK: 0001452804
Recently Updated • Analysis: Apr 9, 2026 • SEC Data: 2022-12-31
STRONG SELL
95% Conf
Pending
Analysis scheduled

📊 RMHI Key Takeaways

Revenue: $0.0
Net Margin: N/A
Free Cash Flow: $-30.9K
Current Ratio: 0.00x
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence

Is RMHI a Good Investment? Thesis Analysis

Claude

RMHI exhibits critical insolvency with negative stockholders equity of -$603.4K and zero revenue generation. The company is depleting its minimal cash reserves with negative operating cash flows while incurring persistent operating losses, indicating operational collapse. Severely outdated financial data (Dec 2022) prevents current assessment and combined with balance sheet insolvency suggests extreme distress.

Why Buy RMHI? Key Strengths

Claude
  • + Minimal cash reserves of $96.7K provide limited operational runway
  • + No long-term debt obligations reported
  • + Low total asset base limits downside exposure to creditors

RMHI Investment Risks to Consider

Claude
  • ! Negative stockholders equity of -$603.4K indicates technical insolvency and bankruptcy risk
  • ! Zero revenue with negative operating cash flow of -$30.9K demonstrates no viable business operations
  • ! Financial data from December 2022 is extremely outdated, preventing accurate current assessment and potential delisting risk

Key Metrics to Watch

Claude
  • * Current stockholders equity and solvency status
  • * Cash burn rate and months of runway remaining
  • * Any evidence of revenue generation or operational activity resumption

RMHI Financial Metrics

Revenue
$0.0
Net Income
$-112.2K
EPS (Diluted)
$0.00
Free Cash Flow
$-30.9K
Total Assets
$102.5K
Cash Position
$96.7K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

RMHI Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -109.5%
FCF Margin N/A

RMHI vs Healthcare Sector

How Retrieve Medical Holdings, Inc. compares to Healthcare sector averages

Net Margin
RMHI 0.0%
vs
Sector Avg 12.0%
RMHI Sector
ROE
RMHI 0.0%
vs
Sector Avg 15.0%
RMHI Sector
Current Ratio
RMHI 0.0x
vs
Sector Avg 2.0x
RMHI Sector
Debt/Equity
RMHI 0.0x
vs
Sector Avg 0.6x
RMHI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is RMHI Overvalued or Undervalued?

Based on fundamental analysis, Retrieve Medical Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

RMHI Balance Sheet & Liquidity

Current Ratio
0.00x
Quick Ratio
-0.32x
Debt/Equity
N/A
Debt/Assets
688.8%
Interest Coverage
-60.33x
Long-term Debt
N/A

RMHI 5-Year Financial Trend & Growth Analysis

RMHI 5-year financial data:
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Retrieve Medical Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.

RMHI Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

RMHI Quarterly Performance

Quarterly financial performance data for Retrieve Medical Holdings, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2017 N/A $9.8K N/A
Q2 2017 N/A -$5.5K N/A
Q1 2017 N/A -$1.9K N/A
Q3 2016 N/A -$9.8K N/A
Q2 2016 N/A -$590.1K N/A
Q3 2015 $178.8K -$488.5K N/A
Q2 2015 $149.6K -$320.5K N/A
Q1 2015 $117.4K -$525.6K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

RMHI Capital Allocation

Operating Cash Flow
-$30.9K
Cash generated from operations
Stock Buybacks
$125.0K
Shares repurchased (TTM)
Dividends
None
No dividend program

RMHI SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for Retrieve Medical Holdings, Inc. (CIK: 0001452804)

📋 Recent SEC Filings

Date Form Document Action
Feb 9, 2023 10-Q pkph123122-10q.htm View →
Jan 20, 2023 8-K form_8k.htm View →
Dec 19, 2022 10-K pkph093022-10k.htm View →
Dec 19, 2022 10-Q pkph063022-10q.htm View →
Dec 19, 2022 10-Q pkph033122-10q.htm View →

Frequently Asked Questions about RMHI

What is the AI rating for RMHI?

Retrieve Medical Holdings, Inc. (RMHI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are RMHI's key strengths?

Claude: Minimal cash reserves of $96.7K provide limited operational runway. No long-term debt obligations reported.

What are the risks of investing in RMHI?

Claude: Negative stockholders equity of -$603.4K indicates technical insolvency and bankruptcy risk. Zero revenue with negative operating cash flow of -$30.9K demonstrates no viable business operations.

What is RMHI's revenue and growth?

Retrieve Medical Holdings, Inc. reported revenue of $0.0.

Does RMHI pay dividends?

Retrieve Medical Holdings, Inc. does not currently pay dividends.

Where can I find RMHI SEC filings?

Official SEC filings for Retrieve Medical Holdings, Inc. (CIK: 0001452804) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is RMHI's EPS?

Retrieve Medical Holdings, Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is RMHI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Retrieve Medical Holdings, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is RMHI stock overvalued or undervalued?

Valuation metrics for RMHI: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy RMHI stock in 2026?

Our dual AI analysis gives Retrieve Medical Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is RMHI's free cash flow?

Retrieve Medical Holdings, Inc.'s operating cash flow is $-30.9K, with capital expenditures of $0.0.

How does RMHI compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 2).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 9, 2026 | Data as of: 2022-12-31 | Powered by Claude AI